Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 13;2(1):77-84.
doi: 10.1002/rth2.12055. eCollection 2018 Jan.

Clinical outcome of patients with a vitamin K antagonist-associated bleeding treated with prothrombin complex concentrate

Marjolein P A Brekelmans  1 , Rahat A Abdoellakhan  2 , Luuk J J Scheres  1   3 , Joseph S Biedermann  4 , Barbara A Hutten  5 , Karina Meijer  2 , Hugo Ten Cate  6 , Menno V Huisman  7 , Marieke J H A Kruip  4 , Saskia Middeldorp  1 , Michiel Coppens  1
Affiliations

Clinical outcome of patients with a vitamin K antagonist-associated bleeding treated with prothrombin complex concentrate

Marjolein P A Brekelmans et al. Res Pract Thromb Haemost. .

Abstract

Background: Vitamin K antagonists (VKA) are used for the treatment of thromboembolism. Patients with severe VKA-associated bleeding require immediate restoration of haemostasis. Clinical studies on the effect of prothrombin complex concentrate (PCC) are heterogeneous with respect to outcome of bleeding.

Objective: To evaluate the clinical outcome of patients treated with PCC for VKA-associated bleeding.

Methods: We performed a cohort study of consecutive patients who received PCC for VKA-related bleeding in five Dutch hospitals. Data were collected by chart review on the bleeding event, international normalized ratio (INR), haemostatic efficacy, thromboembolic (TE) complications, and mortality. The primary outcome was effective haemostasis, assessed by an adaptation of the Sarode criteria with a surrogate outcome for patients with ICH without repeat CT.

Results: One hundred patients were included. Mean age was 74 years, 54% were male and 79% received VKA for atrial fibrillation. Most patients presented with ICH (41%) or GI bleeding (36%). Effective haemostasis was achieved in 67/98 (68%) patients using the adapted classification. Surrogate outcomes were applied for 32 patients and data for two patients was missing. Median pre-treatment INR was 3.9 (IQR 2.9-5.8). One hour after PCC infusion, the INR was available for 50 patients and of these, 35 (70%) had an INR ≤1.4. TE complications occurred in five patients and 22 died (60% bleeding-related) within 30 days.

Conclusion: PCC achieved effective haemostasis in 68% of evaluable patients with VKA-associated bleeding. TE complication rates were low, but mortality rates were high, due to the large number of patients with ICH.

Keywords: anticoagulants; coumarins; haemorrhage; prothrombin; vitamin K.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Clinical presentation and clinical course of major bleeding episodes (n = 86) on vitamin K antagonists
See this image and copyright information in PMC

References

    1. Holbrook A, Schulman S, Witt DM, et al. Evidence‐based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines. Chest. 2012;141:e152S–84S. - PMC - PubMed
    1. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:257S–98S. - PubMed
    1. Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol. 2008;83:137–43. - PubMed
    1. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception‐cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 1996;348:423–8. - PubMed
    1. Jackson SL, Peterson GM, Vial JH, Daud R, Ang SY. Outcomes in the management of atrial fibrillation: clinical trial results can apply in practice. Intern Med J. 2001;31:329–36. - PubMed

LinkOut - more resources